Summary:- BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with relapsing forms of multiple sclerosis that can be…
ChemRobotics Pvt. Ltd. © 2023, All Rights Reserved.
Designed and Developed by Ample eBusiness
Tag:
U.S. FDA
-
-
RegulatoryU.S FDA
Mallinckrodt Receives U.S. FDA Approval for Terlivaz® (Terlipressin) for Injection for the Treatment of Hepatorenal Syndrome (HRS)
by adminby adminHighlights: Terlivaz is the first and only FDA-approved treatment for adults with HRS involving rapid reduction in kidney function. Terlivaz is expected…
-
Synopsis : Takeda Pharmaceutical Company Limited, a global values-based, R&D-driven biopharmaceutical leader, announced the appointment of Serina Fischer as its General Manager…
-
CompaniesPharma Science & ResearchTakeda
Takeda-Backed Biotech Grabs $24 Million for tRNA-Based Therapies
by adminby adminSummary : hC Bioscience, Inc., a company focused on discovering and developing tRNA-based therapies, announced that it has raised $24 million in…
-
Global MarketPharma Science & Research
Future of work innovation among pharma companies has dropped in the last quarter
by adminby adminSummary : Takeda Pharmaceuticals was the top Future of Work innovator in the pharmaceutical sector in the last quarter. Research and innovation…
-
Global MarketPharma Science & Research
AVEO Oncology to Present Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Third- and Fourth-Line Renal Cell Carcinoma
by adminby adminSummary- Five year follow-up data show FOTIVDA® (tivozanib) patients up to 5X more likely to experience long-term PFS compared to Nexavar® (sorafenib)…
-
Synopsis : Today, the U.S. Food and Drug Administration approved Nexviazyme (avalglucosidase alfa-ngpt) for intravenous infusion to treat patients 1 year of…
-
RegulatoryU.S FDA
Zydus receives final approval from US FDA for Vigabatrin tablets
by adminby adminSummary : Vigabatrin is used to treat babies, one month to two years old with infantile spasms. Zydus has received final approval…
-
Global MarketRegulatoryU.S FDA
Swiss drugmaker Idorsia’s insomnia medicine gets US FDA’s approval
by adminby adminSummary : The drug, to be available under the brand name Quviviq, was approved in doses of 25 mg and 50 mg…
-
AgrochemicalsGlobal Market
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
by adminby adminBlueprint Medicines Corporation a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on…
Newer Posts